Moderna Named a Top Employer by Science for Twelfth Consecutive Year
Key Highlights
- ➤Moderna ranked a top global biopharmaceutical employer for the twelfth consecutive year
- ➤Moderna received EU authorization for mCOMBRIAX in April 2026
- ➤FDA approved Moderna’s seasonal influenza vaccine mFLUSIVA in August 2026
- ➤Moderna and Merck reported positive Phase 3 INTerpath-001 topline results
- ➤2026 survey findings were based on approximately 5,100 completed surveys
Expert Statements
Stéphane Bancel, Chief Executive Officer of Moderna
“At Moderna, we have always believed that the best science happens when talented people are given the opportunity to tackle important problems and make an impact.”
Stéphane Bancel, Chief Executive Officer of Moderna
“To be recognized by Science for twelve consecutive years is a testament to the thousands of people who have helped build and evolve this company.”
Stéphane Bancel, Chief Executive Officer of Moderna
“What continues to unite us is a shared determination to advance mRNA science and translate that work into meaningful advances for patients.”
Tracey Franklin, Chief People and Digital Technology Officer of Moderna
“Being a top employer starts with the strength of our people and what we can accomplish together.”
Tracey Franklin, Chief People and Digital Technology Officer of Moderna
“We are building an organization that brings together the expertise of our people with digital capabilities and AI to solve complex problems in new ways and create an even greater impact for patients.”
CAMBRIDGE, MA / ACCESS Newswire / October 23, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced it was ranked as a top employer in the global biopharmaceutical industry in Science and Science Careers' 2026 Top Employers Survey for the twelfth consecutive year. Moderna was recognized for its corporate image, leadership and direction, and work culture, reflecting its reputation for innovation and quality research, commitment to continuous improvement, and collaborative, data-driven environment.
"At Moderna, we have always believed that the best science happens when talented people are given the opportunity to tackle important problems and make an impact," said Stéphane Bancel, Chief Executive Officer of Moderna. "To be recognized by Science for twelve consecutive years is a testament to the thousands of people who have helped build and evolve this company. What continues to unite us is a shared determination to advance mRNA science and translate that work into meaningful advances for patients."
Get started
Create a free account to read the full story.